Evidence map›Paper›PMID 35130281›Full record

ArticlePloS one2022

A proximity-based in silico approach to identify redox-labile disulfide bonds: The example of FVIII.

Andrea Arsiccio, Clive Metcalfe, Roberto Pisano, Sanj Raut, Carmen Coxon

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Andrea ArsiccioDepartment of Applied Science and Technology, Politecnico di Torino, Torino, Italy.ORCID 0000-0003-3809-4957
Clive MetcalfeNational Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Roberto PisanoDepartment of Applied Science and Technology, Politecnico di Torino, Torino, Italy.
Sanj RautNational Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Carmen CoxonNational Institute for Biological Standards and Control, Hertfordshire, United Kingdom.ORCID 0000-0001-8694-4894
National Institute for Biological Standards and Control · GBPolitecnico di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allosteric disulfide bonds permit highly responsive, transient 'switch-like' properties that are ideal for processes like coagulation and inflammation that require rapid and localised responses to damage or injury. Haemophilia A (HA) is a rare bleeding disorder managed with exogenous coagulation factor(F) VIII products. FVIII has eight disulfide bonds and is known to be redox labile, but it is not known how reduction/oxidation affects the structure-function relationship, or its immunogenicity-a serious complication for 30% severe HA patients. Understanding how redox-mediated changes influence FVIII can inform molecular engineering strategies aimed at improving activity and stability, and reducing immunogenicity. FVIII is a challenging molecule to work with owing to its poor expression and instability so, in a proof-of-concept study, we used molecular dynamics (MD) to identify which disulfide bonds were most likely to be reduced and how this would affect structure/function; results were then experimentally verified. MD identified Cys1899-Cys1903 disulfide as the most likely to undergo reduction based on energy and proximity criteria. Further MD suggested this reduction led to a more open conformation. Here we present our findings and highlight the value of MD approaches.

Indexed as

DisulfidesFactor VIIIMolecular Dynamics SimulationOxidation-ReductionComputer SimulationHemophilia AHumansProtein ConformationDisulfidesFactor VIII

Identifiers

PMID35130281
PMCPMC8820644
OpenAlexW2962134334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.